X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The awards create potential dilution through employee options priced at the stock's September 30 closing price.

Rhea-AI Summary

X4 Pharmaceuticals (XFOR) granted new employees options to purchase 80,000 common shares, effective September 30, 2026, as employment inducement awards.

The options have an exercise price of $2.90 per share, equal to the stock's closing price on September 30, and a ten-year term. Vesting spans four years: 25% after 12 months, followed by monthly vesting over the next 36 months, subject to continued employment. The Compensation Committee approved the awards under the 2019 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Options for 80,000 common shares at $2.90 per share create potential dilution upon exercise.

Key Figures

Options granted: 80,000 shares Exercise price: $2.90 per share Option term: 10 years +1 more

Options granted

80,000 shares

Aggregate options issued to new employees

Exercise price

$2.90 per share

Equal to the September 30, 2026 closing price

Option term

10 years

Term of each option

Vesting schedule

4 years

25% vests after 12 months; the remainder vests monthly over the following 36 months

Historical Context

1 past event · Latest: Sep 01

1 event

1. Sep 01

   Inducement grants

   24h Move

   -0.7%

   Prior grant under the same plan covered 50,000 shares at a $4.04 exercise price.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), exercise price, vesting

3 terms

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"an exercise price of $2.90 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"with 25% of the shares vesting after 12 months"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on September 30, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 80,000 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.

The options have a ten-year term and an exercise price of $2.90 per share, which is equal to the closing price of X4’s common stock on September 30, 2026. Each option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employee’s continued employment with X4 on such vesting dates. The options are subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of an award agreement covering the grant.

About X4 Pharmaceuticals

X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is approved in the U.S. and EU as XOLREMDI^® for patients with WHIM syndrome. The Company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders. The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.

X4 Investor Contact:
Remy Bernarda
Jenny Kobin
IR Advisory Solutions
ir@x4pharma.com

Source: X4 Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement awards did X4 Pharmaceuticals grant to new employees?

X4 granted options to purchase 80,000 common shares, effective September 30, 2026. The options have a $2.90 exercise price per share, equal to the stock's closing price that day, and a ten-year term.

What is the vesting schedule for X4 Pharmaceuticals' September 2026 inducement options?

The options vest over four years, with 25% vesting after 12 months and the remaining shares vesting monthly over the following 36 months. Vesting requires the employee to remain employed by X4 on each vesting date.